New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 22, 2013
15:11 EDTABTEarnings Preview: Abbott's Q4 will be last to include proprietary pharma
Abbott Laboratories (ABT) is scheduled to report Q4 earnings before the market open on Wednesday January 23, with a conference call scheduled for 9:00 am ET. Abbott is engaged in the discovery, development, manufacture, and sale of health care products worldwide. The company recently separated its proprietary pharmaceutical business into AbbVie, an independent company... EXPECTATIONS: Analysts are looking for EPS of $1.50 on revenue of $10.58B, according to First Call. The consensus range for EPS is $1.47-$1.53 on revenue of $10.40B-$10.76B... LAST QUARTER: Abbott reported Q3 EPS of $1.30 against estimates of $1.28 on revenue of $9.77B against estimates of $9.93B. On its Q3 earnings conference call the company said it was too early to give FY13 guidance... STREET RESEARCH: On January 11, Barclays initiated Abbott with an Equal Weight and a $35 price target. Earlier in January, Deutsche Bank downgraded Abbott to Hold from Buy with a $33 price target citing valuation following the spin-off of AbbVie, while Wells Fargo in a research note on January 2 said Abbott shares are attractive following the spin-off, citing significant margin expansion opportunities. Wells Fargo gave a valuation range on Abbott shares of $33-$34 to reflect the spin-off... PRICE ACTION: Shares of Abbott traded in an upward trajectory in 2012 from approximately $56.50 to a high of approximately $72 reached in mid-October. Abbott has traded in a range of approximately $31.64 to $33.88 since the company announced the completion of the spin-off on January 2.
News For ABT From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 13, 2015
10:00 EDTABTOn The Fly: Analyst Downgrade Summary
Today's noteworthy downgrades include: Abbott (ABT) downgraded to Neutral from Buy at Goldman... Advance Auto Parts (AAP) downgraded after Q3 miss at Sterne Agee CRT... CafePress (PRSS) downgraded to Underperform from Market Perform at Raymond James... (CTRP) downgraded to Outperform from Strong Buy at Raymond James... CubeSmart (CUBE) downgraded to Outperform from Strong Buy at Raymond James... Deutsche Bank (DB) downgraded to Neutral from Buy at Citi... Digital Ally (DGLY) downgraded to Neutral from Buy at Roth Capital... El Pollo Loco (LOCO) downgraded to Neutral at Baird... F5 Networks (FFIV) downgraded to Market Perform from Outperform at William Blair... FirstMerit (FMER) downgraded on stock outperformance at Raymond James... Fly Leasing (FLY) downgraded to Underweight from Neutral at JPMorgan... GameStop (GME) downgraded on valuation, digital impact at Pacific Crest... Histogenics (HSGX) downgraded to Neutral from Buy at BTIG... MaxPoint (MXPT) downgraded to Hold from Buy at Needham... Memorial Resource (MRD) downgraded to Outperform at Scotia Howard Weil... Rite Aid (RAD) downgraded to Neutral from Overweight at JPMorgan... Rubicon Minerals (RBY) downgraded to Sell from Hold at Canaccord... SABMiller (SBMRY) downgraded to Hold from Buy at Berenberg... Sensata (ST) downgraded at SunTrust... Stryker (SYK) downgraded to Neutral from Buy at Goldman.
06:26 EDTABTAbbott downgraded to Neutral from Buy at Goldman
Subscribe for More Information
06:24 EDTABTMedtronic upgraded to Conviction Buy from Buy at Goldman
Goldman Sachs analyst David Roman upgraded Medtronic (MDT) to Conviction Buy saying the stock's risk/reward is compelling at current levels. The company's fundamentals are the strongest in nearly a decade amid improving end-markets, new product launches and financial flexibility, Roman tells investors in a research note. He raised his price target for shares to $90 from $87. Roman removed Stryker (SYK) from the Conviction List and also downgraded Abbott (ABT) to Neutral.

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use